Nuveen, LLC Phathom Pharmaceuticals, Inc. Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 101,520 shares of PHAT stock, worth $261,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
101,520Holding current value
$261,921% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
157Shares Held
68.2MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$26.1 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$19.3 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$18.2 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$9.42 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$9.02 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $101M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...